30+ years of combined expertise delivers accelerated, value-driven high-throughput screening solutions

Peapod Bio Inc., a new contract research organization (CRO), launched today offering small molecule assay development and high-throughput screening (HTS) services using label-free and optical technologies. Its innovative mass spectrometry platform, powered by polymeric enrichment arrays (PEAs) and state-of-the-art MALDI instrumentation, accelerates the characterization of biochemical activities and binding interactions for virtually any target.

“We’re here to solve a persistent challenge when outsourcing early phase drug discovery,” said Dr. Zachary Gurard-Levin, CEO and founder of Peapod Bio. “Rather than rely on legacy technologies and rigid, one-size-fits-all processes, we take a flexible and tailored approach, built on collaborative interactions and creative assay design to quickly generate decision-driving data.”

Peapod Bio works as an extension of your lab, integrating seamlessly as true partners in discovery, and delivering reliable data faster than any other CRO. It is poised to become a key driver of early-stage discovery to assist clients in reducing risk and uncovering better therapeutic leads.

About Peapod Bio:

Peapod Bio Inc. leads the industry with an innovative approach to mass spectrometry that rapidly delivers assay development, high-throughput screening, and hit-to-lead solutions for small molecule drug discovery. Guided by rigorous scientific standards and clear, transparent communication, Peapod Bio ensures no surprises in data, timelines, or cost. Whether benefiting from label-free or optical technologies, our expert team works as an extension of your lab to deliver robust, reliable data faster than any other CRO. Discover more at www.peapodbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250903764208/en/

Introducing Peapod Bio: a new CRO redefining drug discovery with label-free assays & high-throughput screening.